The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Just the word "cancer" is enough to fill many people with fright, but one 25-year-old has told Newsweek she is determined to show that a diagnosis—while incredibly challenging—need not mean death ...

T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The European Commission (EC), ...

has made a major breakthrough in treating a common and challenging form of cancer called diffuse large B-cell lymphoma (DLBCL). In a clinical trial known as EPCORE NHL-2, the researchers showed ...